Email
Print
Herpes Zoster (Shingles) Market - By Treatment (Antiviral Medication, Anti-inflammatory Medication & Others), By Route of Administration (ral, Injectables & Others), By End-user (Hospital & Clinics, Ambulatory Care Centers, Elderly Care Centers & Others), By Distribution Chanel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy & Others), By Geography - Global Opportunity Analysis & Industry Forecast, 2022-2027
Herpes Zoster (Shingles) Market Overview
Herpes Zoster (Shingles) Market Size is estimated to reach $275.9 million by 2027 and is poised to grow at a CAGR of 3.5% over the forecast period of 2022-2027. The varicella-zoster virus, which is a common viral infection of the nerves, causes herpes zoster (HZ), also known as shingles. People over 50 years of age and those with weakened immune systems are more likely to develop shingles. According to National Center for Biotechnology Information (NCBI) in March 2021, a cumulative incidence of HZ ranges from 2.9–19.5 cases per 1,000 population and an incidence rate of HZ ranges from 5.23–10.9 cases per 1,000 person-years. Incidence rates (6.05–12.8 versus 4.30–8.5 cases per 1,000 person-years) were higher in females than males. Such growing HZ cases and postherpetic neuralgia and the need for Post Herpetic Neuralgia Treatment and Shingles Vaccine are driving the Herpes Zoster (Shingles) Industry growth.
Herpes Zoster (Shingles) Market Report Coverage
The report: “Herpes Zoster (Shingles) Market Forecast
(2022-2027)" by Industry ARC, covers an in-depth analysis of the following
segments in the Herpes Zoster (Shingles) Market.
Key Takeaways
- Geographically, North America held a dominant market share in the year 2021 owing to the better diagnostic techniques in this region. In addition, various treatments available to cure such infections are further surging the growth of the Herpes Zoster (Shingles) Market Size.
- The Herpes Zoster (Shingles) Market is projected to grow owing to the increase in consumption of immunosuppressant drugs and the growing prevalence of postherpetic neuralgia.
- A detailed analysis of strengths, weaknesses, opportunities and threats will be provided in the Herpes Zoster (Shingles) Market Report.
Herpes Zoster (Shingles) Market: Market Share (%) by region, 2021
For More Details On this report - Request For Sample
Herpes Zoster (Shingles) Market Segment Analysis - by Treatment
Herpes Zoster (Shingles) Market based on treatment can be further
segmented into Antiviral Medication, Anti-inflammatory Medication and Others. The
anti-inflammatory medication segment held a dominant market share in the year
2021 owing to the growing demand for anti-inflammatory drugs like
corticosteroids. The oral use of prednisone which is
in a class of corticosteroids is supposed to be beneficial for treating herpes
zoster infection, thus, driving the growth of the Herpes Zoster (Shingles) Market Share.
However, anti-viral medication is estimated to grow with the fastest CAGR of 4.1% over the forecast period 2022-2027. According to Medscape in July 2021, anti-viral treatments such as aciclovir and its derivatives (valaciclovir, famciclovir, penciclovir and desciclovir) have been shown to be secure and efficient in treating disease, therefore, fuelling the growth of the Herpes Zoster (Shingles) Market Share.
Herpes Zoster (Shingles) Market Segment Analysis - by End-user
Herpes Zoster (Shingles) Market based on end-user can be further
segmented into Hospitals, Ambulatory Care Centers, Elderly Care Centers and
Others. The hospital segment held a dominant market share in
the year 2021 owing to the growing admission regarding HZ infection after the covid-19 vaccination. According to Lancet in February 2022, between February 23 and July 31, 2021, the incidence
of HZ infection and hospitalization was 7.9 for CoronaVac and 7.1 for
BNT162b2 per 1,000,000 doses administered, thus, supporting the Herpes Zoster
(Shingles) Market Share.
However, Elderly Care Centers are estimated to grow with the fastest CAGR of 4.9% over the forecast period 2022-2027 owing to the growing geriatric population and their low immunity increases the chances of Postherpetic Neuralgia and generates the need for Post Herpetic Neuralgia Treatment. According to NCBI in May 2022, in younger, healthy adults, the incidence of HZ ranges from 1.2 to 3.4 per 1,000 people per year, while it is 3.9 to 11.8 per 1,000 people per year in patients over the age of 65. These factors are fueling the growth of the Herpes Zoster (Shingles) Market Share.
Herpes Zoster (Shingles) Market Segment Analysis - by Geography
The Herpes Zoster (Shingles) Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America held a dominant market share of 36% in the year 2021 owing to the availability of Shingles vaccines like aciclovir and recent outbreaks of HZ infection in this region. According to the Center for Disease Control and Prevention (CDC), each year, there are roughly 4 instances of HZ per 1,000 people in the U.S. About 1 per 100 Americans aged 60 and older are affected by the disease each year.
Furthermore, the Asia-Pacific is estimated to grow with the fastest CAGR over the forecast period 2022-2027 owing to the growing aging population and the high risk of HZ infection in this region. According to the World Health Organisation (WHO), the proportion of the aging population in South-East Asia will be increased to 13.7% and 20.3% by 2030 and 2050 respectively in turn fueling the growth of the Herpes Zoster (Shingles) Market Size.
Herpes Zoster (Shingles) Market Drivers
Growing Prevalence of Chickenpox is Driving the Market Growth.
HZ is caused by the reactivation of the varicella-zoster virus (VZV), the same virus that causes varicella (chickenpox). According to the WHO, an estimated approximately 4.2 million varicella cases with severe complications and around 4,200 related deaths occur per year in the world. However, a secondary attack rate higher than 70% has been described in unvaccinated groups. Also, according to the WHO, since the beginning of 2022, 1,536 suspected cases with 72 deaths were reported from eight countries as of 8 June 2022 and 59 confirmed cases were reported from six countries during this same period. Such a growing prevalence of chickenpox increases the inclination toward Post Herpetic Neuralgia Treatment and Shingles Vaccine, is driving the growth of the Herpes Zoster (Shingles) Market.
Advanced Diagnostic Techniques is Propelling the Herpes Zoster (Shingles) Market Growth.
Laboratory testing is advised to confirm the diagnosis if clinical
symptoms alone are inconclusive, particularly in patients who have received the
recommended shingles vaccination and in people with weakened immune systems. To
diagnose the infection accurately the advanced technique of Polymerase Chain
Reaction (PCR) is mostly used owing to its high specificity and quick
turnaround time. According to ScienceDirect in June 2020, the
success rate of RT-PCR was 98.3% for herpes simplex viruses 1 (HSV-1) and 99.3%
for varicella-zoster virus (VZV), therefore, driving the growth of the Herpes Zoster (Shingles) Industry.
Herpes Zoster (Shingles) Market Challenge
High
Cost of Treatment is Hampering Market Growth.
Congenital HZ is
a serious global cause of morbidity. Globally, the prevalence of HZ is rising
and it costs the healthcare system and society billions of dollars per year
through lost productivity. Annually in the U.S. alone, it is estimated that
HZ results in $2.6 billion in direct medical costs. Also in 2019, the Czech
Republic introduced HZ vaccination with RZV for the first
time into the country’s national vaccine schedule. However, the national health
system does not cover the cost of vaccination, therefore, limiting the growth of the Herpes Zoster (shingles)
Industry growth.
Herpes Zoster (Shingles) Industry Outlook
Product launches, mergers and acquisitions, joint ventures and
geographical expansions are key strategies adopted by players in the Herpes
Zoster (Shingles) Market. The top 10 companies in the Herpes Zoster (Shingles)
Market are:
- Abbott Laboratory
- Bausch Health
- Cipla Inc.
- Camber Pharmaceuticals.
- GlaxoSmithKline plc.
- Merck & Co.
- Novartis AG.
- Pfizer Inc.
- Eli Lilly and Co.
- Teva Pharmaceutical Industries Ltd.
Recent Developments
- In June 2022, Camber Pharmaceuticals announced the addition of Emtricitabine and Tenofovir Disoproxil Fumarate Tablets to their current portfolio. Emtricitabine and Tenofovir Disoproxil Fumarate Tablets are a two-drug combination of emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF), both HIV-1 nucleoside analog reverse transcriptase inhibitors and is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 37 lbs.
- In April 2022, Bausch Health Companies Inc. announced it has entered into an arrangement agreement with its wholly owned subsidiary Bausch + Lomb Corporation, a leading global eye health business of Bausch Health Companies, Inc.
- In July 2019, Cipla (EU) Ltd, a U.K.-based wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited and Jiangsu Acebright Pharmaceutical Co. Ltd. announced that they have entered into an agreement to set up a joint venture company (“JV Co”) in the People’s Republic of China.
Relevant Titles
Report Code: HCR 0022
Report Code: HCR 39388
Report Code: HCR 0905
For more Lifesciences and Healthcare Market reports, please click here